Home | Articles
Published on:August 2020
Indian Journal of Pharmaceutical Education and Research, 2020; 54(3):509-516
Review Article | doi:10.5530/ijper.54.3.99

Therapeutic Potential of Chymase Inhibitors in Cardiovascular Diseases: An Overview

Authors and affiliation (s):

Qutaiba Ahmed Al Khames Aga1*, Anroop B. Nair2, Wafa Hourani1, Subramani Parasuraman3, Mueen Ahmed KK4 , Nagaraja Sreeharsha2

1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, JORDAN.

2Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.

3Unit of Pharmacology, Faculty of Pharmacy, AIMST University, Bedong, Kedah, MALAYSIA.

4Phcog.Net, #17, II Floor, Buddha Vihar Road Cox Town, Bangalore, Karnataka, INDIA.


Chymase belongs to the family of serine proteases and is mainly warehoused in a heparin proteoglycan macromolecular complex within the mast cells. Extensive studies have been carried out in the last few decades to assess the role of chymase in human diseases. Recent studies have shown the significance of chymase in blood pressure regulation owing to its efficient angiotensin II forming activity. Angiotensin II-generation routes that are associated with human cardiovascular diseases have pathophysiological importance which is still argumentative. Chymase inhibitors play a distinctive role in regulating the renin-angiotensin system as compared to the inhibitors of angiotensin-converting enzyme and type 1 angiotensin II receptor. Therefore, this mechanism may have a role in medical applications of chymase inhibitors by inactivation of the local renin-angiotensin system to avoid cardiovascular diseases. This review highlights the significant role of chymase inhibitors as a potential approach for the management of cardiovascular diseases such as atherosclerosis, hypertension, vascular proliferation, myocardial infarction and heart failure.

Key words: Chymase inhibitors, Angiotensin II, Angiotensin-converting enzyme, Mast cells, Blood pressure regulator, Cardiovascular diseases.



Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the 2019 Release of Journal Citation Reports (source: 2018 Web of Science Data).


Impact Factor® as reported in the 2018 Journal Citation Reports® (Clarivate Analytics, 2019): 0.425

User login

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.


IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs